What is specialty access worth to your organization?
Nova is Livemed's deployment intelligence platform. SVI is its predictive scoring framework. Together they answer five questions about any hospital — directional in three minutes.
Built on 6,899 specialty encounters across 22 hospitals and the methodology in The Geography of Specialty Care.
How Nova runs an assessment.
One assessment. Five questions answered.
Each module is a lens on the same model — geography, admissions, specialty mix and public data resolved into decision-grade intelligence.
"How much value could specialty access create?"
Specialty Value Index™
A 0–100 score predicting where specialty access generates the most multiplied value.
Flagship index"Which specialties should we deploy?"
Specialty Opportunity Analysis
Models the gap across ID, cardiology, pulmonology, nephrology and critical care.
"What transfers could we retain locally?"
Transfer Analysis
Estimates transfers you could keep local — geography-weighted to the 37.4% anchor.
"What is the financial opportunity?"
Financial Impact Model
Retained revenue, CMI lift, reduced locum dependence — conservative, base and optimistic bands.
"What does this mean for our community?"
Community Impact Analysis
Patients kept close to home, travel avoided, workforce stability, local economic value.
"What’s the optimal rollout?"
Deployment Planner
Sequences a multi-facility rollout by impact-per-dollar — aligned to the $50B RHTP.
RHTP-alignedDifferent organizations. Different questions. One model.
Livemed Intelligence isn't only for rural hospitals. It reframes the same predictive engine for everyone deciding where specialty access creates value.
For cost-based and margin-pressured facilities, every avoided transfer preserves admissions, case mix, and community trust. The model quantifies what specialty access is worth before you commit.
- Geography-weighted transfer retention
- CMI lift and retained-revenue bands
- RHTP merit alignment for funding
- Workforce stability modeling
Nova answers five questions.
Not a score. A decision-support platform. SVI is one component inside Nova — the way PageRank sits inside Google Search.
Should we pursue this hospital?
Which specialties first?
Which products?
What ROI?
What deployment sequence?
The moat isn't the score. It's the stack.
Public signals are commodity. SVI is the predictive scoring framework. Nova is the recommendation engine. Virtualis is the execution layer. Network learning is what compounds.
- Layer 01Public SignalsCommodity
CMS, HRSA, CDC, Census — the same data every analyst can access.
- Layer 02SVISemi-proprietary
The predictive scoring framework — specialty-fit mapping and opportunity ranges on top of public signals.
- Layer 03NovaHighly proprietary
The recommendation engine. Answers which hospital, which specialties, which products, what ROI, what sequence.
- Layer 04Virtualis®Very proprietary
The execution layer — the operational platform no one else runs.
- Layer 05Network LearningThe compounding moat
Every deployment retrains SVI and Nova against real operational outcomes.
Every hospital we deploy improves our ability to identify, prioritize, implement, and optimize the next one.
Five layers a competitor can't rebuild from public data alone.
CMS, HRSA, CDC, Census. The same data every analyst can access.
The predictive scoring framework. Specialty-fit mapping and economic recommendations over public signals.
The recommendation engine. Which hospital, which specialties, which products, what ROI, what sequence.
The execution layer. The operational platform no competitor runs.
Every deployment retrains SVI and Nova against real outcomes — sequencing, adoption, ROI, transfers.
Weights, formulas and archetype rules are confidential. What we describe publicly is the architecture, not the internals.
How Nova compounds across the network.
Public data tells you what any analyst can see. SVI predicts fit on top of it. What competitors can't rebuild is Nova underneath — the recommendation engine that retrains on real deployment outcomes. The score is table stakes; the network is the moat.
"This hospital behaves like Hospital #37." Similarity-based recommendations replace generic scoring.
Cardiology first, pulmonology second, ID third — orderings validated by real outcomes.
Which physician groups actually engage, per archetype and deployment pattern.
Financial ranges tighten as real deployment outcomes accrue.
Recommendations sharpen as the network grows — deployment sequencing, specialty prioritization, adoption prediction, transfer avoidance and ROI calibration all retrain on real operational outcomes.
Every state has been awarded RHTP funding (FY2026–FY2030), half by merit. Livemed Intelligence produces the impact-per-dollar evidence that case requires, mapped to the program's five goals.
Model your RHTP opportunityKnow your opportunity before you invest.
Assess in under three minutes. Verified organizations unlock the full report — RHTP alignment, financial modeling and deployment plan.
Specialty Value Index™ is a trademark of Livemed Health, Inc. All outputs are directional estimates pending facility-specific validation — not a CMS compliance determination. RHTP figures per CMS (December 2025) and KFF analysis.